Skip to content

Biogen beats revenue, profit views in 2Q

July 25, 2017

Biogen Inc. BIIB, +4.11% shares surged 5.8% in premarket trade Tuesday after the company reported second-quarter profit and revenue beats. Earnings for the latest quarter fell to $863 million, or $4.07 per share, from $1.05 billion, or $4.79 per share in the year-earlier period. Adjusted earnings-per-share were $5.04, compared with the FactSet consensus of $4.37. Revenue rose to $3.08 billion from $2.89 billion, compared with the FactSet consensus of $2.81 billion. Biogen, which spun out its hemophilia business into the company Bioverativ BIVV, +0.63% in the first-quarter, said it excluded all hemophilia revenues from the second quarter of 2016. The latest results include a 5% increase in multiple sclerosis revenues as compared with the prior year, a 13% increase in revenue for the multiple sclerosis drug Tecfidera as compared with the prior year and $203 million in revenue for the spinal muscular atrophy therapy Spinraza, which was only approved at the very end of 2016. Biogen also raised its 2017 financial guidance due to “faster than anticipated adoption of Spinraza in the U.S.,” increasing revenue outlook to about $11.5 to $11.8 billion and EPS outlook to between $20.80 and $21.40, up from $20.45 to $21.25. Biogen shares have slumped 0.8% over the last three months, compared with a 3.4% rise in the S&P 500 SPX, -0.11%


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: